Program
relmapirazin
Also written as “MB-102”, “Lumitrace” and “MB-102 and commercially available optical angiography imaging system”.
Its studies are mostly in Renal Insufficiency · Retinal Diseases · Blastic Plasmacytoid Dendritic Cell Neoplasm · Renal Insufficiency, Chronic · Acute Kidney Injury, led by 3 companies.
Drug pageRelmapirazin: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| MediBeaconits history only | 62 open or running | phase 3since Apr 21, 2022 | May 10, 2016 | Dec 2026phase 1 · NCT07080008 |
| Huadong Medicineits history only | 10 open or running | phase 3since Mar 22, 2023 | Mar 22, 2023 | none ahead |
| Mustang Bio | 10 open or running | phase 2since Sep 25, 2019 | Sep 25, 2019 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Mustang Bio only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jun 9, 2017Named relmapirazinINNProposed as its International Nonproprietary Name in WHO's List 117 · before, MB-102
- Sep 25, 2019First study: phase 2 study in Blastic Plasmacytoid Dendritic Cell NeoplasmFirst studyNCT04109482 · 3 enrolled · United States
TargetBeta
“A preparation of genetically modified autologous T-cells transduced with a replication incompetent, self-inactivating (SIN) lentiviral vector expressing a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD123 (interleukin-3 receptor alpha chain or IL3RA) and ”NCIt, by rule
Other programs on IL3RA
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pivekimab sunirinerule | AbbVie | phase 3 | 4 |
Studies
The one study Mustang Bio leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04109482Blastic Plasmacytoid Dendritic Cell Neoplasm · United States | 2 | Terminated | May 17, 2023 | 3 |
How it is read
Names in the registry
- “MB-102”, 4 entries
- “Lumitrace”, 1 entry
- “MB-102 and commercially available optical angiography imaging system”, 1 entry
- “MB-102 OMID”, 1 entry
- “MB-102-- single dose of 4 µmol/kg”, 1 entry
Codes read as this program: MB102.
Conditions, from the studies’ own filings
- Renal Insufficiency, 2 studies
- Retinal Diseases, 1 study
- Blastic Plasmacytoid Dendritic Cell Neoplasm, 1 study
- Renal Insufficiency, Chronic, 1 study
- Acute Kidney Injury, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.